Announcement PDF IMPROVING THE LIVES OF PEOPLE WITH NEURODEVELOPMENTAL DISABILITIES Corporate Presentation 2 September 2026 Forward looking statements This presentation contains forward looking statements that involve risks and uncertainties. Although we believe that the expectations reflected in the forward looking statements are reasonable at this time, Neuren can give no assurance that these expectations will prove to be correct. Actual results could differ materially from those anticipated. Reasons may include risks associated with drug development and manufacture, risks inherent in the regulatory processes, delays in clinical trials, risks associated with patent protection, future capital needs or other general risks or factors. 2 Large potential upside for shareholders is enabled by financial strength 3 *Rett and Fragile X syndromes are licensed to Acadia, with same economics to Neuren as trofinetide; Neuren retains worldwide rights to all other indications Phelan-McDermid syndrome (PMS) Pitt Hopkins syndrome (PTHS) Hypoxic Ischemic Encephalopathy (HIE) Angelman syndrome, Prader-Willi Syndrome, SYNGAP1, Rett syndrome (Acadia)*, Fragile X syndrome (Acadia)* NNZ-2591 2 indications prioritised for maximum commercial impact Long-term income growth from DAYBUE® (trofinetide)1 A$543m income from DAYBUE since launch in 2023 A$287 million cash as at 30 Jun 2026 1 Refer to www.acadia.com for DAYBUE (trofinetide) US prescribing and important safety information. Trofinetide is approved in the EU, Canada and Israel. Trofinetide is not approved in Australia 2 NNZ-2591 is an investigational medicine and is currently not approved for sale in any country 4 A uniquely positioned ASX biotech company Sustainable growing royalty income from DAYBUE, driven by strong momentum in US and ongoing global expansion Recurring royalty supplemented by significant milestone payments Multiple potential indications beyond PMS, with development prioritised for maximum commercial impact NNZ-2591 value potential to be unlocked through successful execution of PMS Phase 3 study Attractive DAYBUE commercial model with 100% pretax profit margin for Neuren Prioritised pipeline fully funded, with surplus cash enabling opportunities to optimise total shareholder return Targeting serious neurodevelopmental conditions with urgent unmet need 5 Impaired communication between neurons across synapses, abnormal formation/pruning of dendrites, chronic inflammation Rett (MECP2) Fragile X (FMR1) Phelan-McDermid (SHANK3) Pitt Hopkins (TCF4) Angelman (UBE3A) | Prader-Willi (15q11-q13) | SYNGAP1-related disorder (SYNGAP1) Neurodevelopmental disorders Hypoxic-Ischemic Encephalopathy (lack of oxygen or blood flow to the brain before, during or shortly after birth) Brain injury Walking and balance issues Anxiety and hyperactivity Seizures Impaired communication Intellectual disability Impaired social interaction Developmental delays Cognitive impairment Seizures Cerebral palsy Impaired hand use Sleep disturbance Gastrointestinal problems Severe impact on nearly every aspect of life Long-term impact on survivors Excitotoxicity, mitochondrial dysfunction, acute and chronic inflammatory processes Neuren’s drugs target the critical role of insulin-like growth factor 1 (IGF-1), using analogs of naturally occurring peptides that can be taken orally as liquids Synapses DAYBUE (trofinetide) Exclusively licensed to Acadia Pharmaceuticals globally 6 Strong DAYBUE sales momentum driving sustainable royalty growth 7 Refer to www.acadia.com for DAYBUE (trofinetide) US prescribing and important safety information. Trofinetide is approved in the EU, Canada and Israel. Trofinetide is not approved in Australia * Full year estimates based on Acadia full year 2026 DAYBUE Net Sales Guidance of US$480-510m The only approved treatment for Rett syndrome in US, EU, Canada and Israel 8.5 10.4 9.6 12.9 53 18 37 42 56 CY2023 CY2024 CY2025 CY2026E* Royalty to Neuren (US$m) 85 101 96 125 480 177 348 391 510 CY2023 (Apr -Dec) CY2024 CY2025 CY2026E Acadia Guidance DAYBUE Global Net Sales (US$m) +23–30% + 24–33% Q2 Q2 Q1 Q1 Strong adoption of new powder formulation STIX in the US exceeding expectations DAYBU® launch in Germany anticipated in early Q4 2026 0% 25% 50% 75% 100% 0% 20% 40% 60% 80% 100% % penetration rate % total diagnosed patients Significant upside potential in the US 8 Delphi expert consensus panel recently recommended DAYBUE as part of the standard of care for eligible patients with Rett syndrome1 Refer to www.acadia.com for DAYBUE (trofinetide) US prescribing and important safety information. Trofinetide is approved in the EU, Canada and Israel. Trofinetide is not approved in Australia 1 Prange EO, Beisang A, Pehlivan D, et al. Expert Consensus on Real-World Use of Trofinetide for Rett Syndrome Using a Modified Delphi Method. Ann Child Neurol. 2026; 4:38-51. 2 Acadia Q1 2026 Earnings Call DAYBUE STIX accelerating engagement with new and returning patients • Limited launched in Q1 2026 focusing on Centers of Excellence (COEs) • Broadly available from early Q2 2026 • 40% of all US DAYBUE patients now receiving STIX • 45% of STIX demand in Q2 were from new or returning patients US Penetration Rate2 COEs Outside COEs Approved Aug 2026 9,000 - 12,000 Rett patients1 Phase 3 results Sep–Nov 2026 1,000 Rett patients1 Approved Mar 2023 6,000 - 9,000 Rett patients1 Long term growth opportunity through global expansion 9 Tiered Royalty Rates (% of net sales)3 1 Acadia estimates 2 Each milestone payment is payable once only 3 Royalty rates payable on the portion of annual net sales that fall within the applicable range Future Sales Milestones2 Future Development Milestones2 US$35m following 1st commercial sale in Europe US$15m following 1st commercial sale in Japan Net Sales in a CY US$m ≥US$500m 50 ≥US$750m 100 ≥US$1bn 150 Annual Net Sales Rates ≤US$250m 10% >US$250m, ≤US$500m 12% >US$500m, ≤US$750m 14% >US$750m 15% Up to US$170m on achievement of escalating annual net sales thresholds Up to US$110m on achievement of escalating annual net sales thresholds Mid-teens to low-20s % of net sales Mid-teens to low-20s % of net sales NNZ-2591 (ercanetide) 10 NNZ-2591 targets the critical role of IGF-1 in synapses 11 Cellular responses Pre- synaptic neuron Post- synaptic neuron Neurotransmitters Synapses IGFBP IGF-1 IGFBP NNZ-2591 IGF-1R IGF-1 activity is regulated by binding proteins (IGFBPs) that bind IGF-1 and prevent it from acting at its receptor (IGF-1R), reducing signaling NNZ-2591 increased the availability of IGF-1 to trigger signaling at IGF-1R in vitro1, increasing the amount of signaling IGF-1 IGF-1R IGF-1 regulates synaptic transmission NNZ-2591 increases IGF-1 availability1 and attenuates neuroinflammation2 1 Guan et al. Sci. Rep. 2014;4:4388. doi: 10.1038/srep04388 2 Evaluation of the neuroprotective effects of NNZ-2591 in a mouse model of neonatal hypoxic-ischemic encephalopathy. University of Nebraska Medical Center, 2025. Unpublished data on file IGF-1 promotes the delivery of neurotransmitter receptors into the membrane. This directly increases the amplitude of the postsynaptic response IGF-1 regulates synaptic vesicle dynamics. By enhancing neurotransmitter release, IGF-1 increases synaptic transmission NNZ-2591 is the first investigational medicine in Phase 3 for Phelan- McDermid syndrome (PMS) 12 The Voice of the Patient…..1 “PMS has an overwhelming unmet medical need. There are no FDA approved treatments for PMS despite its severely debilitating manifestations. Parents and caregivers are open to trying almost anything to try to relieve their child’s suffering; most have tried an incredibly high number of treatments and approaches for symptom management, with very little success.” NNZ-2591 program ✓ Alignment with FDA on single Phase 3 trial design and endpoints to support a New Drug Application ✓ Koala Phase 3 trial enrolling in US and Canada ✓ Meaningful improvements rated by clinicians and caregivers in open-label Phase 2 trial2 ✓ Supported by positive effects and dose response in shank3 model of PMS3 ✓ Orphan Drug designation (US and EU) ✓ Rare Pediatric Disease designation (US) ✓ Fast Track designation (US) NNZ-2591 is an investigational medicine and is currently not approved for sale in any country 1 Excerpts from Voice of the Patient Report of Externally-Led Patient-Focused Drug Development Meeting Nov 2022 2 NEU-2591-PMS-001: An Open-Label Study of the Safety, Tolerability, and Pharmacokinetics of Oral NNZ-2591 in Phelan- McDermid Syndrome - 13 weeks treatment of patients age 3-12 years at 4 US sites 3 The impact of NNZ-2591 on the phenotype of the shank3 KO mouse model of Phelan-McDermid syndrome. GeN.DDi, 2019. Unpublished data on file Developmental delay/intellectual impairment (lack of safety awareness) and communication issues are the most troublesome concerns. Improved cognitive functioning and improved communication are the most desired outcomes. “PMS has severe quality of life impacts on those living with the disease, as well as on parents and siblings. Most activities of daily life, including communicating needs or wants, self-care (bathing, dressing, toileting) and socializing with peers/siblings are affected. Most individuals living with PMS rely on their parents and caregivers for all their daily needs, and many require 24-hour care.” 13 NNZ-2591 Placebo 160 80 80 Double-blind, 13 weeks NNZ-2591 Open label, 12 months Randomised 1:1 giving estimated 95% power for each co- primary endpoint Koala - the first ever Phase 3 trial in PMS Screening 4 - 6 weeks Same age range (3-12) and same length of treatment (13 weeks) as Phase 2 Target dosing equivalent to dose tested in Phase 21 ~20 trial sites, mostly in US Program fully funded from existing cash NNZ-2591 is an investigational medicine and is currently not approved for sale in any country 1 12.5 mg/kg per day in Phase 3 vs 12 mg/kg in Phase 2, and titration period two weeks in Phase 3 vs six weeks in Phase 2 Alignment with FDA on single Phase 3 trial design and endpoints to support a NDA 14 Co-primary Endpoints in Phase 2 Results1 Phelan-McDermid Syndrome Assessment of Change (PMSA-C), previously referred to as CGI-I in Phase 2 16/18 subjects showed improvement Mean score: 2.4 (P < 0.00012) Receptive Communication sub-domain of the Vineland Adaptive Behavior Scales, 3rd Edition (VABS-3 Receptive-Raw Score) 16/18 subjects showed improvement Mean improvement: 7.5 (from baseline of 29.0) 3 (P = 0.00012) 3 Key Phase 3 endpoints robustly positive in Phase 2 trial Key Secondary Endpoint in Phase 2 Results1 Caregiver Impression of Change (CIC) score 15/18 subjects showed improvement Mean score: 2.7 (P = 0.00032) NNZ-2591 was well tolerated in Phase 2, with no clinically meaningful changes in safety parameters during treatment NNZ-2591 is an investigational medicine and is currently not approved for sale in any country 1 NEU-2591-PMS-001: An Open-Label Study of the Safety, Tolerability, and Pharmacokinetics of Oral NNZ-2591 in Phelan-McDermid Syndrome - 13 weeks treatment of patients age 3-12 years at 4 US sites 2 Wilcoxon signed rank test - p-values are nominal without type 1 error control 3 Based on post hoc analysis of overall VABS-3 secondary endpoint 15 Neuren’s leadership in science and community for PMS Recent published study supported by Neuren estimating the prevalence of PMS to be 1 in 7,300 people (~39,000 in North America2) Honoured to support and participate in the biannual PMSF Family Conference as the Presenting Sponsor Koala Phase 3 study1 continues to gain momentum 16 trial sites in US/Canada activated 100+ patients referred to sites or await site activation 8 sites activated in OLE for completers of 13-weeks study First patient from Phase 2 study enrolled in OLE NNZ-2591 is an investigational medicine and is currently not approved for sale in any country 1 Koala is a randomised, double-blind, placebo-controlled clinical trial evaluating the safety and efficacy of NNZ-2591 for 13 weeks in approximately 160 children aged 3 to 12 years and a 52- week open-label extension study 2 Estimate based on United Nations population data 2025, derived by applying the estimated prevalence rate to the populations under 60 years Aiming for the first investigational medicine in Phase 3 for Pitt Hopkins syndrome (PTHS) 16 NNZ-2591 program ✓ Type B End of Phase 2 meeting with FDA scheduled for Oct 2026 to align Phase 3 study ✓ Clinical improvements observed by clinicians and caregivers in Phase 2 trial1 ✓ Positive effects observed in tcf4+/- model of PTHS2 ✓ Orphan Drug designation (US and EU) ✓ Fast Track designation (US) ✓ Rare Pediatric Disease designation (US) NNZ-2591 is an investigational medicine and is currently not approved for sale in any country 1 NEU-2591-PTHS-001: An Open-Label Study of the Safety, Tolerability, and Pharmacokinetics of Oral NNZ-2591 in Pitt Hopkins syndrome - 13 weeks treatment of patients age 3-17 years at 5 US sites 2 Drug Validation Initiative. Gen.DDi, 2019. Unpublished data on file 3 Wilcoxon signed rank test - p-values are nominal without type 1 error control • 13 weeks treatment of patients age 3-17 years in open label trial at 5 US sites • Mean CGI-I of 2.6 with 9 out of 11 children showing improvement (p = 0.00393) Phase 2 trial highlights1 Improvements were seen in clinically important aspects of Pitt Hopkins syndrome, including: • communication • social interaction • cognition; and • motor abilities Multiple late-stage opportunities wholly owned by Neuren 17 NNZ-2591 is an investigational medicine and is currently not approved for sale in any country 18 A milestone-rich roadmap Q3 2026 Q4 2026 2027 Japan trial top-line results DAYBUE (trofinetide) 1 NNZ-2591 (ercanetide) 2 Commercial launch in Germany Acadia Q3 26 results US$35m 1st EU commercial sale milestone payment Japan NDA submission Acadia Q4 26 results Commencement of juvenile animal toxicity study to support HIE IND End of Phase 2 meeting with FDA to align PTHS Phase 3 study IND application and FDA meeting for HIE Periodic updates on Koala progress PTHS Externally-Led Patient-Focused Drug Development (EL-PFDD) Meeting with the FDA 1 Refer to www.acadia.com for DAYBUE (trofinetide) US prescribing and important safety information. Trofinetide is approved in the EU, Canada and Israel. Trofinetide is not approved in Australia 2 NNZ-2591 is an investigational medicine and is currently not approved for sale in any country CONTACT investorrelations@neurenpharma.com 19